MX2012001999A - Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. - Google Patents

Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.

Info

Publication number
MX2012001999A
MX2012001999A MX2012001999A MX2012001999A MX2012001999A MX 2012001999 A MX2012001999 A MX 2012001999A MX 2012001999 A MX2012001999 A MX 2012001999A MX 2012001999 A MX2012001999 A MX 2012001999A MX 2012001999 A MX2012001999 A MX 2012001999A
Authority
MX
Mexico
Prior art keywords
diabetes
type
metabolic diseases
treating cardiovascular
nkg2d
Prior art date
Application number
MX2012001999A
Other languages
English (en)
Inventor
na Xiong
Mingcan Xia
David H Raulet
Jacob Sten Petersen
Thora Brynja Boedvarsdottir
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2012001999A publication Critical patent/MX2012001999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención proporciona métodos, composiciones y equipos para tratar y detectar diabetes tipo 2 y/o condiciones que pueden ser reguladas o normalizadas mediante la inhibición de NKG2D, tal como enfermedades cardiovasculares.
MX2012001999A 2009-08-17 2010-08-16 Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. MX2012001999A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23442509P 2009-08-17 2009-08-17
US30411310P 2010-02-12 2010-02-12
PCT/US2010/045627 WO2011022334A1 (en) 2009-08-17 2010-08-16 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes

Publications (1)

Publication Number Publication Date
MX2012001999A true MX2012001999A (es) 2012-02-29

Family

ID=43014101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001999A MX2012001999A (es) 2009-08-17 2010-08-16 Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.

Country Status (11)

Country Link
US (2) US20120148581A1 (es)
EP (1) EP2467152B1 (es)
JP (2) JP5838158B2 (es)
KR (1) KR20120090931A (es)
CN (1) CN102548573B (es)
AU (1) AU2010284428B2 (es)
BR (1) BR112012002353A2 (es)
CA (1) CA2769409A1 (es)
MX (1) MX2012001999A (es)
RU (2) RU2566264C2 (es)
WO (1) WO2011022334A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2747785A4 (en) * 2011-08-26 2015-04-15 Univ California METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION
BR112014014558A8 (pt) * 2011-12-16 2017-07-04 Atopix Therapeutics Ltd composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004236636B2 (en) * 2003-03-24 2010-02-04 The Scripps Research Institute DNA vaccines against tumor growth and methods of use thereof
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
DK1732588T3 (da) * 2004-04-05 2009-10-12 Univ California Modulation af NKG2D
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
CN105001333B (zh) * 2007-12-14 2019-05-17 诺沃—诺迪斯克有限公司 抗人nkg2d抗体及其用途

Also Published As

Publication number Publication date
KR20120090931A (ko) 2012-08-17
RU2015138677A (ru) 2018-12-25
RU2012105528A (ru) 2013-09-27
BR112012002353A2 (pt) 2018-03-13
JP2013502420A (ja) 2013-01-24
EP2467152A1 (en) 2012-06-27
EP2467152B1 (en) 2017-05-17
AU2010284428A1 (en) 2012-02-16
AU2010284428B2 (en) 2014-09-11
CN102548573A (zh) 2012-07-04
JP5838158B2 (ja) 2015-12-24
RU2566264C2 (ru) 2015-10-20
JP2016014030A (ja) 2016-01-28
JP5978362B2 (ja) 2016-08-24
CN102548573B (zh) 2016-03-16
CA2769409A1 (en) 2011-02-24
US20150376281A1 (en) 2015-12-31
US20120148581A1 (en) 2012-06-14
WO2011022334A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
TWI367886B (en) Proteasome inhibitors and methods of using the same
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2010005080A (es) Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
IN2015DN01197A (es)
IN2015DN01161A (es)
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012040499A3 (en) Metabolic inhibitors
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
WO2008067219A3 (en) Quinazolinone modulators of tgr5
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
MX2009010057A (es) Compuesto de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de beta-secretasa.
EP2603214A4 (en) HETEROARYLE AND USES THEREOF
WO2016061509A8 (en) Compositions and methods of treating muscular dystrophy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal